Go to
JCI Insight
Citations to this article
Madhav V. Dhodapkar
Published February 25, 2019
Citation Information: J Clin Invest. 2019;129(4):1522-1523. https://doi.org/10.1172/JCI127581.
Citation Information: J Clin Invest. 2019;129(4):1522-1523. https://doi.org/10.1172/JCI127581.
Abstract
Genetically engineered T cells have shown promising activity in the treatment of cancer. However, these cells are also potentially susceptible to immune-suppressive pathways in the tumor microenvironment that may limit their efficacy. In this issue of the JCI, Yamamoto et al. describe a new cellular engineering approach to prevent Fas-mediated inhibition of T cell function, which may be exploited to improve cellular therapy for cancer.
Authors
Madhav V. Dhodapkar
Citation information
Citations to this article (1)
| Title and authors | Publication | Year |
|---|---|---|
|
Myofibroblasts persist through immune privilege mechanisms to mediate oral submucous fibrosis: Uncovering the pathogenesis.
Sharma M, Shetty SS, Soi S, Radhakrishnan R |
Journal of oral biology and craniofacial research | 2024 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)